The Patent No. 8,343,486, which is entitled as ‘Methods and Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation’, covers the use of various topical formulations comprising a combination of the retinoid Vitamin A and the blood vessel dilator methyl nicotinate in a stable emulsion.
In addition, the formulations can also include additional retinoids or blood vessel dilators and an antioxidant and/or a mitochondrial function promoter for treating wounds and ulcers associated with diabetic neuropathy, or myopathy, cancer, or from a physical injury to the location, claims the company.
BioChemics president John Masiz said the new technology allows the company to begin the development of new treatments for wounds that have a difficult time healing.
"The type of wound we are dealing with here are generally ulcerative and are very difficult to treat with current treatment options; things like bed sores, diabetic foot ulcerations, traumatic injury etc," Masiz added.
